Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company focused on developing abuse-deterrent and overdose-prevention formulations for opioid and stimulant therapeutics. The company went public through a SPAC merger in 2021 and filed a 10-K/A amendment with the SEC on June 8, 2021, reflecting updates to its annual disclosure as a newly listed public entity. Operating in the healthcare and drug-delivery technology sector, Ensysce centers its pipeline on proprietary MPAR and TAAP platform technologies designed to deter misuse of controlled substances. For full filing history, deal terms, and current status on ENSC, sign up for complete data on SpacDesk.